skip to content »
Baylor Licensing Group
Press Release and News Archives
- Baylor College of Medicine and ImmunoVac, Inc., have entered into an exclusive, worldwide license agreement for the rights to develop a novel approach to immunotherapy involving the suppression of negative immune regulators. - May 15, 2007
- Baylor College of Medicine and Advantagene Inc. have entered into an agreement to allow Advantagene to license the exclusive, worldwide rights to intellectual property related to a novel cancer immunotherapy. - April 30, 2007
- LigoCyte Pharmaceuticals Initiates U.S. Phase I Clinical Trial of Norovirus Vaccine that Incorporates Virus-like Particle Technology Licensed from Baylor College of Medicine - April 3, 2007
- VGX Pharmaceuticals, Inc., announced today that it has signed a license agreement with Baylor College of Medicine covering a broad range of Growth Hormone Releasing Hormone and related intellectual property for applications in humans. - May 14, 2007
- Immusol announces an exclusive worldwide license agreement with Baylor College of Medicine for a novel cancer therapy. - January 31, 2006
- TyRx Pharma, Inc., announces the signing of exclusive license agreement with Baylor College of Medicine and The University of Texas M. D. Anderson Cancer. Center - January 30, 2006
Better World Reports: How academic research contributs to society